In mouse tumors, the systemic inhibition of ROCK hindered tumor progression by decreasing the expression of tumor-derived PD-L1, which in turn resulted in increased infiltration of CD4+ and CD8+ T cells (Meng et al., 2020). This evidence concerns the gene CD4 and neoplasm.